If you have ever wondered why some people experience dramatic weight loss on medications like Ozempic or Mounjaro while others struggle to see results, the answer may be written in your DNA.
A large-scale study recently published in Nature suggests that genetic variations play a significant role in determining both how effectively GLP-1 medications work and how much discomfort—such as nausea—a patient might endure.
The Genetic Blueprint of Weight Loss
Researchers from 23andMe conducted an extensive study involving nearly 28,000 people currently using GLP-1 medications (including semaglutide and tirzepatide). The findings highlight a crucial link between specific genes and treatment outcomes:
- The GLP1R Gene: This gene encodes the receptor that these drugs target to regulate appetite and blood sugar. Researchers identified a specific variant (rs10305420 ) that is directly linked to increased efficacy.
- Measurable Impact: Individuals carrying this variant lost approximately 1.67 lbs more per copy of the allele compared to those without it.
- Validation: The results were successfully replicated in a separate cohort of over 4,800 participants from the All of Us research program, confirming the legitimacy of this genetic connection.
This discovery helps explain why efficacy varies across different ethnic groups. The study noted that this specific variant was most prevalent in those of European (40%) and Middle Eastern (38%) ancestry, while being significantly less common in those of African ancestry (7%).
The Connection Between Efficacy and Side Effects
One of the most striking revelations of the study is that the same genetic markers that drive weight loss may also drive side effects.
For many, nausea and vomiting are the primary hurdles when starting these medications. The research suggests that these side effects are not just random discomforts but are biologically connected to how the drug interacts with the body.
The “Double Hit” for Tirzepatide Users
The study highlighted a specific risk for users of tirzepatide (Mounjaro/Zepbound), which is a dual agonist targeting both GLP-1 and GIP receptors.
* A variant in the GIPR gene was linked to a higher risk of vomiting.
* Patients who carried variants in both the GLP1R and GIPR genes faced a 14.8-fold increased odds of experiencing vomiting compared to those without these variants.
Beyond Genetics: What Else Drives Results?
While genetics are a major factor, they are not the only variable. The researchers found that non-genetic factors account for about 21% of the variance in weight loss. When combined with genetic data, these factors explain roughly 25% of the total difference in how people respond to the drugs.
Key non-genetic influences identified include:
– Biological Sex: Women tended to see a slightly higher reduction in BMI (12.2%) compared to men (10.0%).
– Medication Type: Tirzepatide users generally saw more weight loss than semaglutide users over similar timeframes.
– Health Status: Individuals with Type 2 diabetes experienced slightly less weight loss (about 2.87 percentage points less) than those without the condition.
– Dosage and Duration: The amount of medication and how long a person has been taking it remain critical factors.
The Future: Toward Precision Obesity Medicine
This research moves us closer to the era of pharmacogenetics —a branch of medicine where doctors use a patient’s genetic profile to predict drug responses before a prescription is even written.
While genetic testing for GLP-1 response is not yet available in clinical practice, this study provides a roadmap for the future. Eventually, instead of a “one size fits all” approach, healthcare providers may be able to tailor treatments to an individual’s unique biology, selecting the specific medication and dosage most likely to maximize weight loss while minimizing gastrointestinal distress.
The Bottom Line: Individual responses to GLP-1 medications are not random; they are deeply influenced by a complex interplay of genetics, ancestry, and lifestyle. This research marks a significant step toward personalized treatment for obesity.
